You are here

  • Home
  • Archive
  • Volume 9, Issue 7
  • Co-delivery of novel bispecific and trispecific engagers by an amplicon vector augments the therapeutic effect of an HSV-based oncolytic virotherapy

Article info

Article menu
XML
Oncolytic and local immunotherapy
Original research
Co-delivery of novel bispecific and trispecific engagers by an amplicon vector augments the therapeutic effect of an HSV-based oncolytic virotherapy

Authors

  • Divya Ravirala Center for Nuclear Receptors and Cell Signaling, Department of Biology and Biochemistry, University of Houston, Houston, Texas, USA PubMed articlesGoogle scholar articles
  • Brandon Mistretta Center for Nuclear Receptors and Cell Signaling, Department of Biology and Biochemistry, University of Houston, Houston, Texas, USAUH Seq-N-Edit Core, Department of Biology and Biochemistry, University of Houston, Houston, Texas, USA PubMed articlesGoogle scholar articles
  • Preethi H Gunaratne Center for Nuclear Receptors and Cell Signaling, Department of Biology and Biochemistry, University of Houston, Houston, Texas, USAUH Seq-N-Edit Core, Department of Biology and Biochemistry, University of Houston, Houston, Texas, USA PubMed articlesGoogle scholar articles
  • Guangsheng Pei Center for Precision Health, School of Biomedical Informatics, The University of Texas Health Science Center at Houston, Houston, Texas, USA PubMed articlesGoogle scholar articles
  • Zhongming Zhao Center for Precision Health, School of Biomedical Informatics, The University of Texas Health Science Center at Houston, Houston, Texas, USA PubMed articlesGoogle scholar articles
  • Xiaoliu Zhang Center for Nuclear Receptors and Cell Signaling, Department of Biology and Biochemistry, University of Houston, Houston, Texas, USA PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Xiaoliu Zhang; shaunzhang{at}uh.edu
View Full Text

Citation

Ravirala D, Mistretta B, Gunaratne PH, et al
Co-delivery of novel bispecific and trispecific engagers by an amplicon vector augments the therapeutic effect of an HSV-based oncolytic virotherapy
Journal for ImmunoTherapy of Cancer 2021;9:e002454. doi: 10.1136/jitc-2021-002454

Publication history

  • Accepted May 16, 2021
  • First published July 6, 2021.
Online issue publication 
November 02, 2022

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.